Bli medlem
Bli medlem

Du är här


Alzinova: Communiqué from the Annual General Meeting of Alzinova AB (publ) on 14 May 2020

Alzinova AB (publ) held its annual general meeting today, 14 May 2020,
in Gothenburg. The annual general meeting elected Chairman of the
Board Björn Larsson to chair the meeting. Anders Sandberg, alternate
board member, was appointed to keep the minutes. The general meeting
passed resolutions in in all proposed matters in accordance with the
Board of Directors's and the shareholders Mivac Developments' and GU
Ventures previously disclosed proposals. The resolutions passed are
summarized below.


The annual general meeting resolved in accordance with the Board's
proposal that no dividend be paid for the financial year 2019.

Board of Directors, auditor and fees

Björn Larsson, Clas Malmeström, Carol Routledge, Anders Waas and
Pernilla Sandwall were re-elected as board members. Lena Degling
Wikingsson and Per-Göran Gillberg were elected as new members of the
board. As alternates, Anders Sandberg and Jesper Dahlberg were

It was resolved that a fee amounting to two times the income base
amount of 2020 be paid to the Chairman of the Board and a fee of one
time the income base amount of 2020 to each of the other ordinary
members of the Board.

The audit firm Ernst & Young Aktiebolag was re-elected as auditor,
with Andreas Mast as auditor in charge.

The Board of Directors and the Managing Director were discharged from

Authorization for the Board of Directors to issue shares, convertibles
and subscription warrants

The annual general meeting resolved to authorize the Board of
Directors during the period until the next Annual General Meeting, on
one or more occasions, to resolve on a new issue of shares,
subscription warrants, or convertible bonds with or without deviation
from the shareholders' preferential rights. If a new share issue is
carried out with preferential rights for the shareholders, the number
of additional shares issued shall not be subject to other limitations
than those that are stipulated by the Articles of Association
regarding share capital and number of shares at the time of the
issue. If an issue is carried out with deviation from the
shareholders' preferential rights, the total number of shares issued
shall not exceed the number that results in a ten (10) percent
dilution for existing shareholders.

Resolution to introduce long-term incentive programmes for the board
and key personnel

The annual general meeting resolved in two separate decisions to
introduce long-term incentive programmes, which shall be carried out
through the issuance of subscription warrants to the board members of
the company, in accordance with the proposal of shareholders Mivac
Developments and GU Ventures, and to key personnel in the company, in
accordance with the Board of Directors's proposal.

The two resolutions entail that the company shall issue no more than
160,000 subscription warrants, each of which entitling the holder to
subscribe for one share in the company. The warrants shall be issued
to the company's board members, with the subscription per member
limited to no more than 10,833 warrants, and to employees and
consultants of the company, with the CEO of the company having the
right to subscribe for no more than 53,000 warrants, the CFO of the
company no more than 21,000 warrants, and other executive employees
(two persons) no more than 10,500 warrants each, in accordance with
the proposals included in the convocation of the general meeting. The
proposal further contains information regarding the dilutive effect
from the resolutions.

"We are very happy to welcome Lena and Per-Göran as new board members
of Alzinova AB. With their experience, the two of them will
contribute valuable skills to the board as the Company now makes the
transition into a new phase," says Björn Larsson, Chairman of the

For more information, please contact:

Kristina Torfgård, CEO

Telephone: +46 70 846 79 75


Certified Adviser:

Corpura Fondkommission AB


Telephone: 0768-532822


About Alzinova AB

Alzinova AB is engaged in pharmaceutical research and development for
treatment of Alzheimer's disease - one of our major health scourges,
without efficient treatment options. The Company's patented
technology enables the development of novel therapies, that with high
precision could target the substances involved in the formation of
the disease and render them harmless. Alzinova's focus is to develop
a vaccine as a long-acting therapy for treatment and prevention of
Alzheimer's disease. The vaccine is currently under preclinical
development, in preparation for human clinical trials. The Company
further conducts development relating to the disease. Alzinova was
founded by researchers from the MIVAC research center at the
University of Gothenburg, and by GU Ventures AB.


Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.